This phenomenon was more significant when higher CD8-positive T cell infiltration was observed in the tumor microenvironment10, which implied that PD-1/PD-L1 inhibitors might provide clinical benefits in patients with EGFR-mutant NSCLC and high PD-L1 expression. The gene discussed is CD8A; the disease is neoplasm.